Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 104

Sort by

Sort Order Select

Journal Articles

Novel PD-L1 Blocking Peptide with Mitochondrial Targeting Sequence: A Strategy to Counteract Resistance in T-Cell Immunotherapy for Myeloma

Smriti Gurung, Colin Crean, David Lloyd Halladay, Judith L. Anderson, Rafat Abonour, Brian A. Walker, Kelvin P. Lee, John Mitchell Chirgwin, Attaya Suvannasankha

Blood (2024) 144 (Supplement 1): 6861.

https://doi.org/10.1182/blood-2024-211787

Published: 2024

Journal Articles

Influence of Myeloma Cell Expressed CD28 and CD86 on BCMA CAR T Cell Efficacy and Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS)

Ehsan Malek, Kimberly Crasti, Grant Schofield, Shernan G. Holtan, Megan M Herr, Marco Davila, You-Wen Qian, Brian Betts, Mackenzie Lieberman, Jason Tong, Colin Chavel, Kelvin P. Lee, Scott Olejniczak

Blood (2024) 144 (Supplement 1): 3445.

https://doi.org/10.1182/blood-2024-198255

Published: 2024

Journal Articles

Unraveling the Kinase-Independent Autoregulatory Mechanism of PIM2 in Multiple Myeloma

Christopher Rolf Schorr, Daniela Nicoleta Petrusca, Louise Carlson, Joyce Hardwick, Julia Grace Reinke, Kelvin P. Lee

Blood (2024) 144 (Supplement 1): 4666.

https://doi.org/10.1182/blood-2024-193753

Published: 2024

Journal Articles

Role of Tryptophan Metabolizing Enzymes in Multiple Myeloma Survival

Julia Grace Reinke, Peng Peng, Daniela Nicoleta Petrusca, Kanita Chaudhry, Louise Carlson, Christopher Rolf Schorr, Kelvin P. Lee

Blood (2024) 144 (Supplement 1): 3350.

https://doi.org/10.1182/blood-2024-211044

Published: 2024

Journal Articles

Interleukin-1 blockade in patients with Wiskott-Aldrich syndrome: a retrospective multinational case series

Blood (2024) 144 (16): 1699–1704.

https://doi.org/10.1182/blood.2024024524

Published: 2024

Includes: Supplemental data

Journal Articles

SDC2 Expression Is Increased in Myeloma Cells in Response to Loss of Pro-Survival Surface Proteins, CD28 and CD86

Veronica Canarte, Tyler Moser-Katz, Catherine Gavile, Benjamin G. Barwick, Kelvin P. Lee, Lawrence H. Boise

Blood (2023) 142 (Supplement 1): 3299.

https://doi.org/10.1182/blood-2023-190453

Published: 2023

Journal Articles

Memory T Cell Donor Lymphocyte Infusion As a Treatment for Viral Reactivations after Pediatric Haploidentical Hematopoietic Stem Cell Transplant

Yixian Li, Wilson Yau Ki Chan, Ka Leung Daniel Cheuk, Pamela P. Lee, Wing H. Leung

Blood (2023) 142 (Supplement 1): 3544.

https://doi.org/10.1182/blood-2023-184877

Published: 2023

Journal Articles

Characterization of Anthropometric Changes in Patients with Relapsed/Refractory Myeloma Treated with BCMA Bispecific Antibody Teclistamab

Setarah Mohammad Nader, S. Tyler Jines, Christopher Collier, Teresa Zimmers, Rafat Abonour, Sherif Farag, Mohammad Abu Zaid, Kelvin P. Lee, Attaya Suvannasankha

Blood (2023) 142 (Supplement 1): 6683.

https://doi.org/10.1182/blood-2023-182754

Published: 2023

Journal Articles

Unraveling Diverse Mechanisms of Complex Structural Variant Interactions through Multiomic Data in Multiple Myeloma

Enze Liu, Nathan Becker, Parvathi Sudha, Aneta Mikulasova, Mohammad Abu Zaid, Attaya Suvannasankha, Kelvin P. Lee, Rafat Abonour, Brian A. Walker

Blood (2023) 142 (Supplement 1): 641.

https://doi.org/10.1182/blood-2023-186262

Published: 2023

Journal Articles

Prospective Molecular Characterization of Multiple Myeloma Patient Samples Identifies High-Risk Patients and Informs Treatment Sequences through Resistance Mechanisms to Immunotherapies

Phillip Pham, Parvathi Sudha, Lin Wang, Wen Niu, Cameron Morgan, Cameron Ligocki, Ramzi Al-Azzawi, Reynold Ly, Francesco Vetrini, Magdalena Czader, Marwan Tayeh, Mohammad Abu Zaid, Kelvin P. Lee, Attaya Suvannasankha, Rafat Abonour, Brian A. Walker

Blood (2023) 142 (Supplement 1): 4738.

https://doi.org/10.1182/blood-2023-180116

Published: 2023

Journal Articles

Teclistamab in Relapsed/Refractory Multiple Myeloma: Real-World Outcomes at a Single Academic Center in the Midwest

Adam Stepanovic, Rafat Abonour, Mohammad Abu Zaid, Sherif Farag, Kelvin P. Lee, Attaya Suvannasankha

Blood (2023) 142 (Supplement 1): 7359.

https://doi.org/10.1182/blood-2023-183085

Published: 2023

Journal Articles

A Phase I Study of Safety, Tolerability and Immunological Effects of SVN53-67/M57-KLH in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance Therapy

Othman Salim Akhtar, Jens Hillengass, Brea Lipe, Sheila A. Figel, Robert A. Fenstermaker, Michael J. Ciesielski, Kelvin P. Lee

Blood (2022) 140 (Supplement 1): 10170–10171.

https://doi.org/10.1182/blood-2022-163597

Published: 2022

Journal Articles

The Pre-Existing T Cell Landscape Is Associated with Response to High Dose Melphalan and Autologous Stem Cell Transplant in Multiple Myeloma

Mohammad Issam Abu Zaid, Parvathi Sudha, Travis S Johnson, Vivek S. Chopra, Cedric E. Dos Santos, Michael Nixon, Attaya Suvannasankha, Sherif S Farag, Kelvin P. Lee, Rafat Abonour, Brian A. Walker

Blood (2022) 140 (Supplement 1): 9919–9920.

https://doi.org/10.1182/blood-2022-167619

Published: 2022

Journal Articles

Response-adapted anti-PD-1–based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE

Blood (2022) 139 (25): 3605–3616.

https://doi.org/10.1182/blood.2022015423

Published: 2022

Includes: Supplemental data

Journal Articles

Single-Cell Tracking By Time Lapse Imaging Confirms Thrombopoietin Promotes Megakaryocytic-Erythroid Progenitor Self Renewal, but Does Not Instruct Lineage Commitment

Blood (2021) 138 (Supplement 1): 3270.

https://doi.org/10.1182/blood-2021-154360

Published: 2021

Journal Articles

CD28 Expression Distinguishes Plasma Cell Fate in Pediatric Patients Suffering from COVID-19/Kawasaki's Disease Vs MIS-C

Adam Utley, PhD, Kelvin P. Lee, MD, Mark Hicar, MD

Blood (2020) 136 (Supplement 1): 8.

https://doi.org/10.1182/blood-2020-143064

Published: 2020

Journal Articles

Tnfα Promotes an Immunosuppressive Microenvironment in Cutaneous T Cell Lymphoma and Regulates PD-L1 Expression

Emine Gulsen Gunes, PhD, Sung Hee Kil, PhD, Xiwei Wu, PhD, Chingyu Su, Zhen Han, Hanjun Qin, PhD, Ting-Fang He, PhD, Jing Chen, Yukiko Yamaguchi, PhD, Jasmine M. Zain, MD, Farah Abdulla, MD, Saul Priceman, PhD, Mingye Feng, PhD, Peter P. Lee, MD, Steven T. Rosen, MD, Christiane Querfeld, MDPhD

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-141070

Published: 2020

Journal Articles

Spatiotemporal Assessment of Immunogenomic Heterogeneity in Multiple Myeloma

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-142622

Published: 2020

Journal Articles

Metabolic engineering against the arginine microenvironment enhances CAR-T cell proliferation and therapeutic activity

Livingstone Fultang, Sarah Booth, Orli Yogev, Barbara Martins da Costa, Vanessa Tubb, Silvia Panetti, Victoria Stavrou, Ugo Scarpa, Andris Jankevics, Gavin Lloyd, Andrew Southam, Steven P. Lee, Warwick B. Dunn, Louis Chesler, Francis Mussai, Carmela De Santo

Blood (2020) 136 (10): 1155–1160.

https://doi.org/10.1182/blood.2019004500

Published: 2020

Includes: Supplemental data

Journal Articles

JCARH125, Anti-BCMA CAR T-cell Therapy for Relapsed/Refractory Multiple Myeloma: Initial Proof of Concept Results from a Phase 1/2 Multicenter Study (EVOLVE)

Sham Mailankody, MBBS, Myo Htut, MD, Kelvin P. Lee, MD, William Bensinger, MD, Todd Devries, PhD, Julia Piasecki, BA, Safiyyah Ziyad, PhD, Michelle Blake, PhD, John Byon, MDPhD, Andrzej Jakubowiak, MD PhD

Blood (2018) 132 (Supplement 1): 957.

https://doi.org/10.1182/blood-2018-99-113548

Published: 2018

NARROW

Novel PD-L1 Blocking Peptide with Mitochondrial Targeting Sequence: A Strategy to Counteract Resistance in T-Cell Immunotherapy for Myeloma

Influence of Myeloma Cell Expressed CD28 and CD86 on BCMA CAR T Cell Efficacy and Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS)

Unraveling the Kinase-Independent Autoregulatory Mechanism of PIM2 in Multiple Myeloma

Role of Tryptophan Metabolizing Enzymes in Multiple Myeloma Survival

Interleukin-1 blockade in patients with Wiskott-Aldrich syndrome: a retrospective multinational case series

SDC2 Expression Is Increased in Myeloma Cells in Response to Loss of Pro-Survival Surface Proteins, CD28 and CD86

Memory T Cell Donor Lymphocyte Infusion As a Treatment for Viral Reactivations after Pediatric Haploidentical Hematopoietic Stem Cell Transplant

Characterization of Anthropometric Changes in Patients with Relapsed/Refractory Myeloma Treated with BCMA Bispecific Antibody Teclistamab

Unraveling Diverse Mechanisms of Complex Structural Variant Interactions through Multiomic Data in Multiple Myeloma

Prospective Molecular Characterization of Multiple Myeloma Patient Samples Identifies High-Risk Patients and Informs Treatment Sequences through Resistance Mechanisms to Immunotherapies

Teclistamab in Relapsed/Refractory Multiple Myeloma: Real-World Outcomes at a Single Academic Center in the Midwest

A Phase I Study of Safety, Tolerability and Immunological Effects of SVN53-67/M57-KLH in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance Therapy

The Pre-Existing T Cell Landscape Is Associated with Response to High Dose Melphalan and Autologous Stem Cell Transplant in Multiple Myeloma

Response-adapted anti-PD-1–based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE

Single-Cell Tracking By Time Lapse Imaging Confirms Thrombopoietin Promotes Megakaryocytic-Erythroid Progenitor Self Renewal, but Does Not Instruct Lineage Commitment

CD28 Expression Distinguishes Plasma Cell Fate in Pediatric Patients Suffering from COVID-19/Kawasaki's Disease Vs MIS-C

Tnfα Promotes an Immunosuppressive Microenvironment in Cutaneous T Cell Lymphoma and Regulates PD-L1 Expression

Spatiotemporal Assessment of Immunogenomic Heterogeneity in Multiple Myeloma

Metabolic engineering against the arginine microenvironment enhances CAR-T cell proliferation and therapeutic activity

JCARH125, Anti-BCMA CAR T-cell Therapy for Relapsed/Refractory Multiple Myeloma: Initial Proof of Concept Results from a Phase 1/2 Multicenter Study (EVOLVE)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only